Contact Us
.
Transparency is No Longer a Compliance Issue

Transparency is No Longer a Compliance Issue

by Meghal Patel, Chief Product Officer for Truzo at Model N. November 11, 2026

Meghal examines why claims-level transparency has become increasingly important as manufacturers navigate the growing complexity of 340B and other drug pricing programs. He argues that greater visibility into pricing, discounts, and utilization can help manufacturers move beyond compliance to improve gross-to-net (GTN) management, revenue forecasting, and strategic decision-making.

To learn more, watch the webinar: From Program Silos to GTN Transparency: A Unified View with Model N + Truzo.

Subscribe to our blog
close-icon

Subscribe to our blog

Join us and get all the latest news. Select your communication preferences, so we can limit our communications to relevant topics.

SELECT All THAT APPLY